Table 3 Comparison of patient characteristics between COVID-19 survivors and non-survivors among patients with cancer during hospital stay. (n = 65)

    Age, years, median

75

72.5

0.212

    Male

13(52)

30(75)

0.057

    Body mass index, kg/m², median

21.04

23.17

0.229

    BMI* < 18

7(28)

5(14.7)

0.210

    BMI* > 24

9(36)

14(41.2)

0.687

    Vaccination doses, median

2

2

0.890

     Ever vaccinated

17(68)

28(70)

0.865

     Full vaccination (> = 3 doses)

12(48)

12(48)

0.875

    DNR*

15(60)

32(80)

0.080

    Smoker

3(12)

17(42.5)

0.024

    Cerebrovascular disease

4(16)

2(5)

0.194

    Dementia

2(8)

3(7.5)

0.941

    Heart failure

1(4)

0(0)

0.202

    Peripheral vascular disease

1(4)

1(2.5)

0.733

    Diabetes mellitus

9(36)

13(32.5)

0.772

    Chronic kidney disease

3(12)

9(22.5)

0.288

    End stage renal disease

1(4)

4(10)

0.377

    Chronic obstructive pulmonary disease

2(8)

2(5)

0.624

    Chronic oxygen use

2(8)

1(2.5)

0.304

    Admitted due to COVID-19

12(48)

20(50)

0.875

    Infected during hospitalization

3(12)

9(22.5)

0.344

    Hematological malignancy

1(4)

6(15)

0.235

    White blood cells, 10⁹/L

8500

12,450

0.006

    Absolute neutrophil count, 10⁹/L

6318.7

7105.45

0.345

    Hemoglobin, g/dL

11.5

10.5

0.153

    Absolute lymphocyte count, 10⁹/L

639.58

531.40

0.571

    Albumin, g/dL

3.1

3.1

0.349

    C-reactive protein, mg/dL

4.78

7.16

0.157

    Procalcitonin, ng/mL

0.51

1.42

0.375

    Ferritin, ng/mL

673.5

3220

< 0.001

    Lactic dehydrogenase, U/L

256

534.5

< 0.001

    Lactate, mg/dL

15.7

33

0.005

    D-dimer, ug/mL

1.570

4.605

0.007

    Fibrinogen, mg/dL

435.6

358

0.188

    Platelet count, /uL

159,000

154,000

0.422

    PaO2/FiO2 ratio, median

148

125.39

0.364

    SOFA* score, median

7

10

0.071

    APACHE* II score, median

22

25.5

0.160

    MAP score**, median

1

3

0.048

    GCS*, median

9

7.5

0.995

    Vasopressor use

6(24)

22(55)

0.014

    Cancer treatment in 4 weeks prior to COVID-19 diagnosis

12(48)

22(55)

0.583

    Cytotoxic chemotherapy in 4 weeks prior to COVID-19 diagnosis

8(32)

11(27.5)

0.698

    Mechanical ventilation

18(72)

24(60)

0.325

    Re-application of MV* after weaning

2(8)

2(5)

0.624

    Tracheostomy

3(12)

1(2.5)

0.121

    New renal replacement therapy during admission

1(4)

9(22.5)

0.044

    Extracorporeal membrane oxygenation

0(0)

5(12.5)

0.066

    Tocilizumab

9(36)

21(52.5)

0.194

    Remdesivir

22(88)

37(92.5)

0.542

    Nirmatrelvir/ritonavir

1(4)

3(7.5)

0.568

    Molnupiravir

1(4)

1(2.5)

0.733

    Enoxaparin

9(36)

13(32.5)

0.772

    Corticosteroid

22(88)

39(97.5)

0.121

    CMV* infection

2(8)

14(35)

0.048

    Gastrointestinal bleeding

6(24)

11(27.5)

0.755

    Thromboembolism

3(12)

4(10)

0.800

    ICU* admission

20(80)

28(70)

0.372

    Hospital length of stay, days, median

33

21.5

0.082

    Ventilator days, median

10

5.5

0.710

    Time from symptoms onset to 1st Ct* > 30, days

14

11.5

0.721

    Prolonged shredding (> 10 days)

18(72)

21(52.5)

0.118